ReviewTranslational research : the journal of laboratory and clinical medicine2017
Gut microbiome and liver disease.
Review in Translational research : the journal of laboratory and clinical medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03285217 (HMB for Denutrition in Patients With Cirrhosis), which is not on this map. Cited by 50 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
HMB for Denutrition in Patients With Cirrhosis (HEPATIC)
Who cites it
50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 101 citations in OpenAlex.
- Diagnostic, prognostic, and therapeutic potentials of gut microbiome profiling in human schistosomiasis: A comprehensive systematic review.PLoS neglected tropical diseases · 2025Pooled it
- Does metabolic dysfunction-associated fatty liver disease increase the risk of chronic kidney disease? A meta-analysis of cohort studies.BMC nephrology · 2024Pooled it
- Chinese Herbal Medicine for Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2022Pooled it
- A randomized controlled trial for response of microbiome network to exercise and diet intervention in patients with nonalcoholic fatty liver disease.Nature communications · 2022Trial
- Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease.Gastroenterology · 2020Trial
- Gut Microbiota, Diet and Lipid Metabolism in Adolescents with NAFLD and Their Role in Preventive Strategies.International journal of molecular sciences · 2026Review
- Research advances on gut microbiota dysbiosis and chronic liver diseases: a review.Frontiers in medicine · 2026Review
- Article
- Intestinal Microbiome in Dogs with Chronic Hepatobiliary Disease: Can We Talk about the Gut-Liver Axis?Animals : an open access journal from MDPI · 2023Article
- Nutritional Support for Liver Diseases.Nutrients · 2023Review
- Gut Microbiota and Neuroinflammation in Acute Liver Failure and Chronic Liver Disease.Metabolites · 2023Review
- Dietary fiber intake and mortality among survivors of liver cirrhosis: A prospective cohort study.Heliyon · 2023Article
- Pathological Connections between Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease.Kidney diseases (Basel, Switzerland) · 2022Review
- The gut-liver axis: host microbiota interactions shape hepatocarcinogenesis.Trends in cancer · 2022Review
- Trust Your Gut: The Association of Gut Microbiota and Liver Disease.Microorganisms · 2022Review
- Compositions of gut microbiota before and shortly after hepatitis C viral eradication by direct antiviral agents.Scientific reports · 2022Article
- Mesenchymal Stem Cell-Derived Extracellular Vesicles in Liver Immunity and Therapy.Frontiers in immunology · 2022Review
- Gut microbiota and calcium balance.Frontiers in microbiology · 2022Review
- Characterization of the Fecal Microbiome in Dogs Receiving Medical Management for Congenital Portosystemic Shunts.Frontiers in veterinary science · 2022Article
- Blood Coral Polysaccharide Helps Prevent D-Gal/LPS-Induced Acute Liver Failure in Mice.Journal of inflammation research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Gut microbiota changes are important in determining the occurrence and progression of chronic liver disease related to alcohol, nonalcoholic fatty liver disease, and cirrhosis. Specifically, the systemic inflammation, endotoxemia, and the vasodilation that leads to complications such as spontaneous bacterial peritonitis and hepatic encephalopathy could be related to the gut milieu. Given the poor prognosis of these events, their prevention and early management are essential. Microbiota may be an essential component of the gut milieu that can impact these clinical events, and the study of their composition and function in a culture-independent manner could help understand the prognosis. Recent human and animal studies have shown that the relative abundance and the functional changes of microbiota in the stool, colonic mucosa, and saliva have varying consequences on the presence and prognosis of chronic liver disease and cirrhosis. The impact of therapies on the microbiota is slowly being understood and will likely lead to a more targeted approach to gut microbiota modification in chronic liver disease and cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.